X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IGC-AD1 (tetrahydrocannabinol) is a small molecule drug that targets neuroinflammation and CB1 receptor dysfunction. It is being evaluated for the treatment of alzheimer disease.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
The net proceeds will be used for the advancement of company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 26, 2024
Details:
IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Lead Product(s): IGC-AD1
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
TGR-63 is a therapeutic candidate designed to disrupt the structure of the amyloid-β (Aβ) peptide, mitigating symptoms such as memory loss and disrupted learning ability, signs of cognitive impairment. It is being evaluated for the treatment of Alzheimer's disease.
Lead Product(s): TGR-63
Therapeutic Area: Neurology Product Name: TGR-63
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
TGR-63 is a patent pending molecule designed to disrupt the structure of Aβ plaque aggregation by disrupting intermolecular interactions and destabilizing their assembly. It is being evaluated in preclinical studies for the treatment of Alzheimer's disease.
Lead Product(s): TGR-63
Therapeutic Area: Neurology Product Name: TGR-63
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties. It is under phase 2 clinical development for the treatment of dementia due to Alzheimer’s.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to alzheimer’s.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research, with IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer’s.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: O-Bank Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 07, 2023
Details:
The funds will support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1 (tetrahydrocannabinol), the Company’s promising investigational drug candidate designed to address agitation in dementia caused by Alzheimer's disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 06, 2023
Details:
IGC-501 (cannabinoid-based therapy) patent filing on the use of cannabinoids in the treatment of seizures. The formulation also received an intent to grant from the European Patent Office.
Lead Product(s): Cannabinoid-based Therapy
Therapeutic Area: Neurology Product Name: IGC-501
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
